THE European Medicines
Agency’s Pharmacovigilance
Risk Assessment Committee has
concluded that the benefits of
Diane 35 (cypoterone acetate
2mg, ethinylestradiol 35ug) and its
generics outweigh the risks, as long
as measures are taken to minimise
the risks of thromboembolism.
The move follows a review
initiated when French authorities
suspended the marketing
authorisation of the contraceptive
(PD 31 Jan) over concerns about
a number of adverse events,
which highlighted “extensive offlabel
use of these medicines as a
contraceptive only”.
The EMA said the medicines
should be used “solely in the
treatment of moderate to severe
acne related to androgen-sensitivity
and/or hirsutism in women of
reproductive age.”The above article was sent to subscribers in Pharmacy Daily's issue from 20 May 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 May 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.